Congratulations to #MBIgraduate Invetx on being acquired by Dechra Pharmaceuticals! We are always so happy to see our #startups' hard work and dedication to their science pay off! #congratulations #startupsuccess #acquired #aquisition #veterinaryscience #therapeutics #monoclonalantibody
We are thrilled to announce that Invetx has agreed to be acquired by Dechra Pharmaceuticals, a global leader in animal health, for up to $520 million on a cash-free and debt-free basis. Our pipeline of monoclonal antibody therapeutics for companion animals and our species-specific, half-life extension technology platform will complement and differentiate Dechra’s broad portfolio of specialty therapeutics for companion animals. We want to thank our numerous veterinary collaborators and their canine and feline patients, technology partners, investors and consultants who have helped create the value at Invetx leading to this important inflection point. The acquisition remains subject to antitrust approval and other customary closing conditions. https://lnkd.in/gWZgvhnM #veterinarybiotherapeutics #companionanimals #animalhealth
